Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 2/3 1

Status

Unknown 3Completed 1

Sponsor Class

OTHER 85INDUSTRY 21NIH 8NETWORK 6OTHER_GOV 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Stomach Neoplasms 3Colorectal Neoplasms 1

Interventions

Capecitabine 28apatinib 25Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Folfox protocol × Clear all
NCT03940131 2022-04-06

REPAN

King Abdullah Medical City

Phase 2 Unknown
30 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03939962 2022-01-26

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Henan Cancer Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02845908 2021-04-23

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Fujian Cancer Hospital

Phase 2 Completed
90 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04155671 2019-11-07

POF Versus FOLFOX Plus IP Paclitaxel in AGC

Fujian Cancer Hospital

Phase 2 Unknown
260 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡